Difference between revisions of "Sunitinib"
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
*PDGFbeta. | *PDGFbeta. | ||
== | ==Uses== | ||
*[[Gastrointestinal stromal tumour]], imatinib-resistant.<ref>{{Cite journal | last1 = Mulet-Margalef | first1 = N. | last2 = Garcia-Del-Muro | first2 = X. | title = Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. | journal = Onco Targets Ther | volume = 9 | issue = | pages = 7573-7582 | month = | year = 2016 | doi = 10.2147/OTT.S101385 | PMID = 28008275 }}</ref> | *[[Gastrointestinal stromal tumour]], imatinib-resistant.<ref>{{Cite journal | last1 = Mulet-Margalef | first1 = N. | last2 = Garcia-Del-Muro | first2 = X. | title = Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. | journal = Onco Targets Ther | volume = 9 | issue = | pages = 7573-7582 | month = | year = 2016 | doi = 10.2147/OTT.S101385 | PMID = 28008275 }}</ref> | ||
*[[Renal cell carcinoma]] - especially [[clear cell renal cell carcinoma]].<ref name=pmid25075067>{{Cite journal | last1 = Yildiz | first1 = I. | last2 = Ekenel | first2 = M. | last3 = Akman | first3 = T. | last4 = Kocar | first4 = M. | last5 = Uysal | first5 = M. | last6 = Kanitez | first6 = M. | last7 = Varol | first7 = U. | last8 = Bayoglu | first8 = IV. | last9 = Tural | first9 = D. | title = Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. | journal = Anticancer Res | volume = 34 | issue = 8 | pages = 4329-34 | month = Aug | year = 2014 | doi = | PMID = 25075067 }}</ref> | *[[Renal cell carcinoma]] - especially [[clear cell renal cell carcinoma]].<ref name=pmid25075067>{{Cite journal | last1 = Yildiz | first1 = I. | last2 = Ekenel | first2 = M. | last3 = Akman | first3 = T. | last4 = Kocar | first4 = M. | last5 = Uysal | first5 = M. | last6 = Kanitez | first6 = M. | last7 = Varol | first7 = U. | last8 = Bayoglu | first8 = IV. | last9 = Tural | first9 = D. | title = Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. | journal = Anticancer Res | volume = 34 | issue = 8 | pages = 4329-34 | month = Aug | year = 2014 | doi = | PMID = 25075067 }}</ref> | ||
Revision as of 13:34, 9 August 2018
Sunitinib (marketed with the brand name Sutent) is a tyrosine kinase inhibitor used to treat renal cell carcinoma (RCC).
In RCC acts on:[1]
- VEGF.
- PDGFbeta.
Uses
- Gastrointestinal stromal tumour, imatinib-resistant.[2]
- Renal cell carcinoma - especially clear cell renal cell carcinoma.[3]
See also
References
- ↑ Toon, CW.; Hasovits, C.; Paik, J.; Field, M.; Chou, A.; Hugh, TJ.; Pavlakis, N.; Gill, AJ. (Jul 2014). "Skin rash, a kidney mass and a family mystery dating back to World War II.". Med J Aust 201 (1): 58-60. PMID 24999901.
- ↑ Mulet-Margalef, N.; Garcia-Del-Muro, X. (2016). "Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives.". Onco Targets Ther 9: 7573-7582. doi:10.2147/OTT.S101385. PMID 28008275.
- ↑ Yildiz, I.; Ekenel, M.; Akman, T.; Kocar, M.; Uysal, M.; Kanitez, M.; Varol, U.; Bayoglu, IV. et al. (Aug 2014). "Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.". Anticancer Res 34 (8): 4329-34. PMID 25075067.